Sign in
ESLAW Stock Price, Chart, Stats & News
Estrella Immunopharma, Inc.
Save
Estrella Immunopharma, Inc. (ESLAW) does not currently pay a dividend.
19.03M
Market cap
–
Current P/E
–
Forward P/E
ESLAW chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.01% |
ROA | -411.19% |
ROE | 185.77% |
D/E | – |
Interest coverage ratio | – |
ESLAW valuation
P/E | – |
P/S | – |
P/B | -3.85x |
P/CF | -22.33x |
P/FCF | -25.09x |
P/OCF | -22.33x |
PEG | -0.56x |
EV multiple | -3.54x |
About
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical firm based in Emeryville, California, dedicated to advancing T-cell immunotherapies for various hematological malignancies and solid tumors within the United States. Its lead investigational treatments include EB103, currently undergoing preclinical assessment for diffuse large B-cell lymphoma, and EB104, which targets both diffuse large B-cell lymphoma and acute lymphocytic leukemia. The company also collaborates with Imugene Limited to develop solid tumor therapies, integrating Imugene's candidate CF33-CD19t with Estrella's EB103.
Similar securities
Based on sector and market capitalization
Report issue